ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/12/2794607/33130/en/ADMA-Biologics-Announces-FDA-Approval-for-BIVIGAM-in-the-Pediatric-Patient-Setting-for-Those-2-Years-of-Age-and-Older.html

Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval

Expanded Label in the U.S. Now Includes Pediatric PI Patients 2 Years of Age and Older

Read more at globenewswire.com

Related news for (ADMA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.